Delcath Systems Closes $9.5 Million Private Placement
20 août 2019 08h00 HE
|
Delcath Systems, Inc.
Bringing total financial amount raised since July 2019 to $29.5M Cash runway past top-line results in 1H2020 with NDA submission anticipated by end of 2020 Recapitalization provides possible...
Delcath Systems Announces $9.5 Million Private Placement
15 août 2019 18h02 HE
|
Delcath Systems, Inc.
NEW YORK, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for...
Delcath Enhances Board of Directors With Appointment of Commercial Leader, John R. Sylvester
29 juil. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces...
Results of Single Center Study on Delcath’s PHP Therapy Published in Cancer Imaging
22 juil. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, July 22, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Systems Closes $20 Million Private Placement
17 juil. 2019 16h05 HE
|
Delcath Systems, Inc.
NEW YORK, July 17, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us” (OTCPK: DCTH) has closed on its previously announced private placement with gross...
Delcath Systems Announces $20 Million Private Placement
11 juil. 2019 13h40 HE
|
Delcath Systems, Inc.
NEW YORK, July 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (“Delcath,” the “Company”, “we”, “our” or “us”) (OTCPK: DCTH) today announced that it has entered into a definitive agreement for...
Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019
16 avr. 2019 08h15 HE
|
Delcath Systems, Inc.
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
28 févr. 2019 10h38 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Health Authority Approval for CHEMOSAT in Brazil
11 févr. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
08 févr. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...